Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver Transplantation | 57 | 2024 | 2330 | 5.660 |
Why?
|
Hepatitis, Autoimmune | 17 | 2023 | 172 | 4.570 |
Why?
|
Cholangitis, Sclerosing | 14 | 2024 | 177 | 2.850 |
Why?
|
Alagille Syndrome | 6 | 2023 | 45 | 1.870 |
Why?
|
Biliary Atresia | 14 | 2018 | 88 | 1.470 |
Why?
|
Liver Failure | 8 | 2013 | 250 | 1.380 |
Why?
|
Liver Diseases | 9 | 2023 | 1297 | 1.350 |
Why?
|
Hepatolenticular Degeneration | 3 | 2022 | 72 | 1.230 |
Why?
|
Immunosuppressive Agents | 21 | 2020 | 4176 | 1.150 |
Why?
|
End Stage Liver Disease | 4 | 2017 | 352 | 1.140 |
Why?
|
Cholestasis | 6 | 2022 | 378 | 0.920 |
Why?
|
Graft Survival | 17 | 2021 | 3820 | 0.900 |
Why?
|
Hypertension, Portal | 7 | 2022 | 226 | 0.860 |
Why?
|
Graft Rejection | 12 | 2021 | 4446 | 0.860 |
Why?
|
Hepatopulmonary Syndrome | 2 | 2014 | 24 | 0.830 |
Why?
|
Autoantibodies | 7 | 2018 | 2118 | 0.770 |
Why?
|
Azathioprine | 4 | 2018 | 354 | 0.740 |
Why?
|
Bile Ducts | 3 | 2012 | 282 | 0.670 |
Why?
|
Cholestasis, Intrahepatic | 4 | 2021 | 75 | 0.650 |
Why?
|
Child | 75 | 2024 | 80158 | 0.630 |
Why?
|
Liver | 15 | 2018 | 7528 | 0.620 |
Why?
|
Liver Cirrhosis, Biliary | 1 | 2018 | 108 | 0.600 |
Why?
|
Fatty Liver | 3 | 2013 | 790 | 0.560 |
Why?
|
Tacrolimus | 6 | 2013 | 733 | 0.550 |
Why?
|
Pediatrics | 6 | 2017 | 3589 | 0.550 |
Why?
|
Bilirubin | 11 | 2021 | 436 | 0.540 |
Why?
|
Pancreas Transplantation | 1 | 2017 | 197 | 0.540 |
Why?
|
Lymphangioma | 1 | 2016 | 61 | 0.520 |
Why?
|
Liver Failure, Acute | 3 | 2014 | 181 | 0.510 |
Why?
|
Medication Adherence | 4 | 2013 | 2176 | 0.500 |
Why?
|
Hepatitis | 3 | 2007 | 228 | 0.500 |
Why?
|
Child, Preschool | 43 | 2023 | 42232 | 0.480 |
Why?
|
Hepatitis C | 4 | 2020 | 1584 | 0.460 |
Why?
|
Organ Transplantation | 3 | 2015 | 1157 | 0.450 |
Why?
|
Fructose Intolerance | 1 | 2013 | 8 | 0.450 |
Why?
|
Gastroenterology | 2 | 2020 | 577 | 0.440 |
Why?
|
Hepatomegaly | 1 | 2013 | 84 | 0.440 |
Why?
|
Bile Ducts, Intrahepatic | 2 | 2021 | 296 | 0.420 |
Why?
|
Liver Neoplasms | 5 | 2017 | 4317 | 0.410 |
Why?
|
Cytochrome P-450 CYP2D6 | 3 | 2003 | 107 | 0.410 |
Why?
|
Adolescent | 58 | 2024 | 88326 | 0.410 |
Why?
|
Autoimmunity | 2 | 2023 | 1356 | 0.410 |
Why?
|
Anemia, Hemolytic, Autoimmune | 3 | 2011 | 147 | 0.400 |
Why?
|
Lymphoproliferative Disorders | 3 | 2012 | 531 | 0.400 |
Why?
|
Hyperplasia | 2 | 2014 | 1152 | 0.380 |
Why?
|
Muromonab-CD3 | 1 | 2011 | 104 | 0.380 |
Why?
|
Tyrosinemias | 1 | 2011 | 10 | 0.380 |
Why?
|
Hepatitis B, Chronic | 3 | 2010 | 410 | 0.380 |
Why?
|
Spleen | 1 | 2017 | 2295 | 0.370 |
Why?
|
Intestine, Small | 1 | 2017 | 1206 | 0.370 |
Why?
|
Infant | 35 | 2023 | 36193 | 0.370 |
Why?
|
Postoperative Complications | 14 | 2017 | 15633 | 0.370 |
Why?
|
Autoimmune Diseases | 1 | 2023 | 2244 | 0.360 |
Why?
|
Giant Cells | 3 | 2007 | 188 | 0.350 |
Why?
|
Portoenterostomy, Hepatic | 5 | 2018 | 22 | 0.350 |
Why?
|
Inflammatory Bowel Diseases | 5 | 2024 | 2422 | 0.340 |
Why?
|
Antilymphocyte Serum | 1 | 2011 | 487 | 0.340 |
Why?
|
Cefotaxime | 1 | 2009 | 35 | 0.330 |
Why?
|
Vancomycin | 2 | 2024 | 503 | 0.330 |
Why?
|
Humans | 114 | 2024 | 761596 | 0.320 |
Why?
|
Continuity of Patient Care | 3 | 2010 | 1069 | 0.320 |
Why?
|
Hepatitis C, Chronic | 5 | 2020 | 1032 | 0.310 |
Why?
|
Thrombocytopenia | 2 | 2016 | 1182 | 0.310 |
Why?
|
Epstein-Barr Virus Infections | 3 | 2012 | 612 | 0.290 |
Why?
|
Treatment Outcome | 34 | 2024 | 64685 | 0.290 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2017 | 2297 | 0.290 |
Why?
|
Cholelithiasis | 1 | 2009 | 407 | 0.290 |
Why?
|
Hyperbilirubinemia, Neonatal | 1 | 2007 | 30 | 0.290 |
Why?
|
Cholangiocarcinoma | 1 | 2013 | 552 | 0.290 |
Why?
|
Bile Duct Neoplasms | 1 | 2013 | 605 | 0.280 |
Why?
|
Self Concept | 1 | 2013 | 1045 | 0.270 |
Why?
|
Caroli Disease | 1 | 2006 | 12 | 0.270 |
Why?
|
Ursodeoxycholic Acid | 2 | 2021 | 81 | 0.260 |
Why?
|
Bile Acids and Salts | 2 | 2021 | 393 | 0.260 |
Why?
|
Male | 68 | 2024 | 360846 | 0.250 |
Why?
|
Williams Syndrome | 1 | 2007 | 194 | 0.250 |
Why?
|
Polycystic Kidney Diseases | 1 | 2006 | 133 | 0.240 |
Why?
|
Methylprednisolone | 3 | 2016 | 385 | 0.240 |
Why?
|
Affect | 1 | 2013 | 1486 | 0.240 |
Why?
|
Pemphigoid, Bullous | 1 | 2006 | 112 | 0.240 |
Why?
|
Interferon-alpha | 2 | 2010 | 921 | 0.240 |
Why?
|
Antiviral Agents | 8 | 2020 | 3060 | 0.240 |
Why?
|
Eosinophilia | 2 | 2012 | 560 | 0.230 |
Why?
|
Female | 68 | 2024 | 392705 | 0.230 |
Why?
|
Infant, Newborn | 17 | 2021 | 26202 | 0.230 |
Why?
|
Treatment Refusal | 2 | 2006 | 429 | 0.230 |
Why?
|
Avitaminosis | 2 | 2014 | 35 | 0.220 |
Why?
|
Jaundice | 1 | 2004 | 94 | 0.220 |
Why?
|
Alanine Transaminase | 6 | 2021 | 603 | 0.220 |
Why?
|
Rubella | 1 | 2023 | 55 | 0.220 |
Why?
|
Lamivudine | 1 | 2005 | 366 | 0.220 |
Why?
|
Chickenpox | 1 | 2023 | 96 | 0.210 |
Why?
|
Mycophenolic Acid | 1 | 2005 | 349 | 0.210 |
Why?
|
Mumps | 1 | 2023 | 71 | 0.210 |
Why?
|
Trientine | 1 | 2022 | 12 | 0.210 |
Why?
|
Hepacivirus | 3 | 2020 | 1336 | 0.210 |
Why?
|
Penicillamine | 1 | 2022 | 60 | 0.210 |
Why?
|
Prednisolone | 3 | 2014 | 326 | 0.200 |
Why?
|
Immunodominant Epitopes | 1 | 2003 | 239 | 0.200 |
Why?
|
Quality of Life | 6 | 2014 | 13367 | 0.190 |
Why?
|
Hemangioendothelioma | 2 | 2013 | 111 | 0.190 |
Why?
|
Cystic Fibrosis | 1 | 2011 | 1285 | 0.190 |
Why?
|
Measles | 1 | 2023 | 183 | 0.190 |
Why?
|
Lung Transplantation | 1 | 2011 | 1310 | 0.190 |
Why?
|
Risk Factors | 18 | 2021 | 74213 | 0.180 |
Why?
|
Chelating Agents | 1 | 2022 | 387 | 0.180 |
Why?
|
Cysts | 1 | 2006 | 681 | 0.180 |
Why?
|
Copper | 1 | 2022 | 369 | 0.170 |
Why?
|
alpha 1-Antitrypsin Deficiency | 1 | 2020 | 112 | 0.170 |
Why?
|
Follow-Up Studies | 14 | 2021 | 39106 | 0.160 |
Why?
|
Retrospective Studies | 22 | 2024 | 80647 | 0.160 |
Why?
|
Adult | 27 | 2024 | 221210 | 0.160 |
Why?
|
Viral Vaccines | 1 | 2023 | 596 | 0.150 |
Why?
|
Sirolimus | 1 | 2005 | 1533 | 0.150 |
Why?
|
Immunologic Factors | 1 | 2007 | 1590 | 0.150 |
Why?
|
Failure to Thrive | 1 | 2018 | 140 | 0.150 |
Why?
|
Young Adult | 16 | 2024 | 59260 | 0.150 |
Why?
|
Enterohepatic Circulation | 1 | 2017 | 12 | 0.140 |
Why?
|
Biopsy | 7 | 2020 | 6766 | 0.140 |
Why?
|
Adrenal Cortex Hormones | 2 | 2018 | 1881 | 0.140 |
Why?
|
Incidental Findings | 2 | 2013 | 697 | 0.140 |
Why?
|
Self Care | 2 | 2013 | 796 | 0.140 |
Why?
|
Glucocorticoids | 3 | 2021 | 2161 | 0.140 |
Why?
|
Adenosine Triphosphatases | 1 | 2021 | 836 | 0.140 |
Why?
|
Gallbladder | 3 | 2017 | 308 | 0.140 |
Why?
|
Ultrasonography | 2 | 2013 | 5971 | 0.140 |
Why?
|
Transplantation | 2 | 2010 | 219 | 0.140 |
Why?
|
Autoantigens | 2 | 2015 | 891 | 0.130 |
Why?
|
Age Factors | 7 | 2021 | 18399 | 0.130 |
Why?
|
Meta-Analysis as Topic | 1 | 2020 | 1380 | 0.120 |
Why?
|
Patient Compliance | 5 | 2013 | 2690 | 0.120 |
Why?
|
Hepatorenal Syndrome | 1 | 2016 | 76 | 0.120 |
Why?
|
Cholangiography | 2 | 2020 | 181 | 0.120 |
Why?
|
Body Weight | 4 | 2018 | 4618 | 0.120 |
Why?
|
Prognosis | 9 | 2021 | 29629 | 0.120 |
Why?
|
North America | 2 | 2016 | 1276 | 0.120 |
Why?
|
Time Factors | 9 | 2021 | 39969 | 0.120 |
Why?
|
Hepatoblastoma | 1 | 2015 | 90 | 0.120 |
Why?
|
Fatal Outcome | 2 | 2017 | 1835 | 0.120 |
Why?
|
Propranolol | 2 | 2013 | 489 | 0.120 |
Why?
|
Risk Assessment | 7 | 2021 | 23996 | 0.120 |
Why?
|
gamma-Glutamyltransferase | 3 | 2021 | 144 | 0.110 |
Why?
|
Donor Selection | 1 | 2016 | 232 | 0.110 |
Why?
|
Diagnosis, Differential | 4 | 2017 | 12973 | 0.110 |
Why?
|
Survival Rate | 4 | 2013 | 12723 | 0.110 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 5841 | 0.110 |
Why?
|
Liver Cirrhosis | 3 | 2023 | 1935 | 0.110 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2016 | 422 | 0.110 |
Why?
|
Fructose-Bisphosphate Aldolase | 1 | 2013 | 51 | 0.110 |
Why?
|
Blood Coagulation Factors | 1 | 2016 | 365 | 0.110 |
Why?
|
Vitamin K | 2 | 2014 | 318 | 0.110 |
Why?
|
Steroids | 1 | 2018 | 929 | 0.110 |
Why?
|
Vincristine | 1 | 2016 | 1036 | 0.110 |
Why?
|
Sarcopenia | 1 | 2018 | 372 | 0.110 |
Why?
|
Jejunum | 2 | 2012 | 472 | 0.110 |
Why?
|
Databases, Factual | 4 | 2015 | 7968 | 0.110 |
Why?
|
Liver Function Tests | 2 | 2012 | 523 | 0.100 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2010 | 1116 | 0.100 |
Why?
|
Reoperation | 5 | 2014 | 4303 | 0.100 |
Why?
|
Recurrence | 5 | 2021 | 8466 | 0.100 |
Why?
|
Severity of Illness Index | 5 | 2024 | 15843 | 0.100 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 2015 | 283 | 0.100 |
Why?
|
Digestive System Surgical Procedures | 1 | 2017 | 572 | 0.100 |
Why?
|
Viremia | 2 | 2012 | 707 | 0.100 |
Why?
|
Vitamin E | 2 | 2014 | 872 | 0.100 |
Why?
|
Hemoglobin SC Disease | 1 | 2011 | 23 | 0.100 |
Why?
|
Focal Nodular Hyperplasia | 1 | 2011 | 29 | 0.100 |
Why?
|
Acetylcysteine | 1 | 2013 | 260 | 0.100 |
Why?
|
Stomach | 1 | 2016 | 696 | 0.100 |
Why?
|
Consanguinity | 1 | 2013 | 456 | 0.090 |
Why?
|
Serum Albumin | 3 | 2021 | 672 | 0.090 |
Why?
|
Calculi | 1 | 2011 | 48 | 0.090 |
Why?
|
Microsomes, Liver | 2 | 2003 | 173 | 0.090 |
Why?
|
Peptide Fragments | 2 | 2003 | 5112 | 0.090 |
Why?
|
Mycoplasma pneumoniae | 1 | 2010 | 43 | 0.090 |
Why?
|
Endoscopy, Digestive System | 1 | 2013 | 351 | 0.090 |
Why?
|
Pneumonia, Mycoplasma | 1 | 2010 | 50 | 0.090 |
Why?
|
Obesity | 1 | 2013 | 12947 | 0.090 |
Why?
|
Graves Disease | 1 | 2012 | 238 | 0.090 |
Why?
|
Anastomosis, Roux-en-Y | 1 | 2010 | 86 | 0.090 |
Why?
|
Antimetabolites | 1 | 2010 | 129 | 0.090 |
Why?
|
Antibodies, Monoclonal | 1 | 2007 | 9177 | 0.090 |
Why?
|
HLA Antigens | 1 | 2015 | 1328 | 0.090 |
Why?
|
Blood Coagulation | 1 | 2016 | 1154 | 0.080 |
Why?
|
Gastrointestinal Tract | 1 | 2016 | 833 | 0.080 |
Why?
|
Anti-Bacterial Agents | 2 | 2024 | 7406 | 0.080 |
Why?
|
Aspartate Aminotransferases | 3 | 2021 | 416 | 0.080 |
Why?
|
Premature Birth | 1 | 2021 | 1782 | 0.080 |
Why?
|
Disease Progression | 4 | 2021 | 13510 | 0.080 |
Why?
|
Allopurinol | 1 | 2010 | 198 | 0.080 |
Why?
|
Acalculous Cholecystitis | 1 | 2008 | 8 | 0.080 |
Why?
|
Cholagogues and Choleretics | 1 | 2008 | 39 | 0.080 |
Why?
|
Transaminases | 2 | 2010 | 199 | 0.080 |
Why?
|
Cohort Studies | 8 | 2024 | 41495 | 0.080 |
Why?
|
Varicose Veins | 1 | 2010 | 155 | 0.080 |
Why?
|
Pilot Projects | 2 | 2013 | 8633 | 0.080 |
Why?
|
Ganciclovir | 1 | 2009 | 252 | 0.080 |
Why?
|
Self Efficacy | 1 | 2013 | 638 | 0.080 |
Why?
|
Biopsy, Needle | 1 | 2013 | 1626 | 0.080 |
Why?
|
Health Behavior | 2 | 2010 | 2644 | 0.080 |
Why?
|
Administration, Oral | 3 | 2024 | 4021 | 0.070 |
Why?
|
Ribavirin | 1 | 2010 | 395 | 0.070 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2010 | 246 | 0.070 |
Why?
|
Colitis, Ulcerative | 1 | 2020 | 1922 | 0.070 |
Why?
|
Mentors | 1 | 2013 | 661 | 0.070 |
Why?
|
Polyethylene Glycols | 2 | 2012 | 1189 | 0.070 |
Why?
|
Drug Monitoring | 2 | 2013 | 962 | 0.070 |
Why?
|
Esophageal and Gastric Varices | 1 | 2010 | 208 | 0.070 |
Why?
|
Regression Analysis | 3 | 2013 | 6345 | 0.070 |
Why?
|
Peer Group | 1 | 2013 | 692 | 0.070 |
Why?
|
Body Image | 1 | 2013 | 638 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 7391 | 0.070 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2011 | 242 | 0.070 |
Why?
|
Patient Dropouts | 1 | 2009 | 412 | 0.070 |
Why?
|
Fibrosis | 1 | 2014 | 2049 | 0.070 |
Why?
|
Fluorescent Antibody Technique | 2 | 2002 | 2467 | 0.070 |
Why?
|
Tissue Donors | 1 | 2016 | 2332 | 0.070 |
Why?
|
Hemangioma | 1 | 2011 | 727 | 0.070 |
Why?
|
Choledochal Cyst | 1 | 2006 | 25 | 0.070 |
Why?
|
Abnormalities, Multiple | 1 | 2013 | 1423 | 0.070 |
Why?
|
Prospective Studies | 9 | 2021 | 54423 | 0.060 |
Why?
|
United States | 8 | 2020 | 72340 | 0.060 |
Why?
|
Diabetes Complications | 1 | 2012 | 1315 | 0.060 |
Why?
|
Transplants | 1 | 2007 | 206 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3415 | 0.060 |
Why?
|
Registries | 4 | 2021 | 8225 | 0.060 |
Why?
|
Vasculitis | 1 | 2009 | 521 | 0.060 |
Why?
|
Platelet Count | 2 | 2020 | 781 | 0.060 |
Why?
|
Food Hypersensitivity | 1 | 2012 | 729 | 0.060 |
Why?
|
Canada | 3 | 2015 | 2122 | 0.060 |
Why?
|
Granuloma, Plasma Cell | 1 | 2005 | 80 | 0.060 |
Why?
|
Colon | 1 | 2012 | 1792 | 0.060 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 694 | 0.060 |
Why?
|
Salvage Therapy | 1 | 2010 | 1263 | 0.060 |
Why?
|
Chickenpox Vaccine | 1 | 2023 | 40 | 0.060 |
Why?
|
Hyperglycemia | 1 | 2012 | 1376 | 0.060 |
Why?
|
Chronic Disease | 4 | 2013 | 9319 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2002 | 3810 | 0.060 |
Why?
|
Double-Blind Method | 5 | 2018 | 12341 | 0.060 |
Why?
|
Gastrointestinal Diseases | 1 | 2012 | 1200 | 0.060 |
Why?
|
Metabolic Diseases | 1 | 2010 | 683 | 0.060 |
Why?
|
Vaccines, Combined | 1 | 2023 | 70 | 0.050 |
Why?
|
Polymerase Chain Reaction | 2 | 2010 | 6075 | 0.050 |
Why?
|
Abdominal Neoplasms | 1 | 2005 | 287 | 0.050 |
Why?
|
Dietary Supplements | 2 | 2014 | 3415 | 0.050 |
Why?
|
Fibrosarcoma | 1 | 2005 | 309 | 0.050 |
Why?
|
Adolescent Behavior | 1 | 2011 | 1190 | 0.050 |
Why?
|
Cytomegalovirus Infections | 1 | 2009 | 831 | 0.050 |
Why?
|
Radioligand Assay | 1 | 2002 | 366 | 0.050 |
Why?
|
Remission Induction | 2 | 2024 | 2397 | 0.050 |
Why?
|
Vaccines, Attenuated | 1 | 2023 | 315 | 0.050 |
Why?
|
Ischemia | 1 | 2011 | 1884 | 0.050 |
Why?
|
Epitope Mapping | 1 | 2003 | 298 | 0.050 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2015 | 3080 | 0.050 |
Why?
|
Postoperative Period | 1 | 2006 | 1814 | 0.050 |
Why?
|
Echocardiography | 1 | 2014 | 4989 | 0.050 |
Why?
|
Insurance Coverage | 1 | 2013 | 1940 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2020 | 14608 | 0.050 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2002 | 239 | 0.050 |
Why?
|
Health Status | 1 | 2014 | 4077 | 0.050 |
Why?
|
Cross Reactions | 1 | 2003 | 817 | 0.050 |
Why?
|
Vitamin A | 2 | 2014 | 613 | 0.040 |
Why?
|
Models, Statistical | 2 | 2013 | 5079 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6938 | 0.040 |
Why?
|
Patient Education as Topic | 1 | 2010 | 2319 | 0.040 |
Why?
|
Immunoglobulin G | 2 | 2005 | 4544 | 0.040 |
Why?
|
Codon, Nonsense | 1 | 2021 | 285 | 0.040 |
Why?
|
Caregivers | 2 | 2009 | 2238 | 0.040 |
Why?
|
Postoperative Care | 2 | 2018 | 1468 | 0.040 |
Why?
|
Viral Nonstructural Proteins | 1 | 2020 | 227 | 0.040 |
Why?
|
Hemorrhage | 1 | 2011 | 3424 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2014 | 2217 | 0.040 |
Why?
|
Insulin Resistance | 1 | 2012 | 3964 | 0.040 |
Why?
|
Acute Kidney Injury | 1 | 2010 | 1924 | 0.040 |
Why?
|
Quality Improvement | 1 | 2013 | 3802 | 0.040 |
Why?
|
Blood Glucose | 1 | 2012 | 6391 | 0.040 |
Why?
|
Insulin | 1 | 2012 | 6597 | 0.040 |
Why?
|
Reference Values | 2 | 2018 | 4920 | 0.040 |
Why?
|
Living Donors | 2 | 2013 | 641 | 0.040 |
Why?
|
Survival Analysis | 3 | 2021 | 10090 | 0.030 |
Why?
|
Cephalometry | 1 | 2018 | 382 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2015 | 20568 | 0.030 |
Why?
|
Prevalence | 2 | 2012 | 15733 | 0.030 |
Why?
|
Comorbidity | 2 | 2010 | 10508 | 0.030 |
Why?
|
Sex Factors | 1 | 2010 | 10554 | 0.030 |
Why?
|
Recovery of Function | 1 | 2006 | 2979 | 0.030 |
Why?
|
Internationality | 1 | 2021 | 1001 | 0.030 |
Why?
|
Epitopes | 1 | 2002 | 2503 | 0.030 |
Why?
|
Cytosol | 1 | 1999 | 888 | 0.030 |
Why?
|
Drug Resistance | 1 | 2021 | 1596 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2010 | 4016 | 0.030 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2015 | 186 | 0.030 |
Why?
|
Hypoalbuminemia | 1 | 2015 | 86 | 0.030 |
Why?
|
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2014 | 26 | 0.030 |
Why?
|
Self Administration | 2 | 2008 | 390 | 0.030 |
Why?
|
Patient Selection | 1 | 2007 | 4244 | 0.030 |
Why?
|
Enterostomy | 1 | 2014 | 14 | 0.030 |
Why?
|
Body Mass Index | 1 | 2012 | 12953 | 0.030 |
Why?
|
Ascites | 1 | 2015 | 338 | 0.030 |
Why?
|
Adrenergic beta-2 Receptor Antagonists | 1 | 2013 | 12 | 0.030 |
Why?
|
Propensity Score | 1 | 2021 | 1913 | 0.030 |
Why?
|
Los Angeles | 1 | 2013 | 243 | 0.030 |
Why?
|
Congenital Hypothyroidism | 1 | 2013 | 40 | 0.030 |
Why?
|
Child Development | 2 | 2018 | 2306 | 0.030 |
Why?
|
Membrane Glycoproteins | 1 | 2023 | 3701 | 0.030 |
Why?
|
Retinol-Binding Proteins | 1 | 2012 | 67 | 0.030 |
Why?
|
Prothrombin Time | 1 | 2012 | 117 | 0.030 |
Why?
|
Gestational Age | 1 | 2021 | 3577 | 0.030 |
Why?
|
Hepatitis A Antibodies | 1 | 2012 | 19 | 0.030 |
Why?
|
Methimazole | 1 | 2012 | 41 | 0.030 |
Why?
|
Antithyroid Agents | 1 | 2012 | 72 | 0.020 |
Why?
|
Splenomegaly | 1 | 2012 | 189 | 0.020 |
Why?
|
Free Radical Scavengers | 1 | 2013 | 211 | 0.020 |
Why?
|
alpha-Tocopherol | 1 | 2012 | 126 | 0.020 |
Why?
|
Hepatic Encephalopathy | 1 | 2013 | 144 | 0.020 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2006 | 4575 | 0.020 |
Why?
|
Hepatitis A | 1 | 2012 | 128 | 0.020 |
Why?
|
Parents | 1 | 2005 | 3563 | 0.020 |
Why?
|
Thyroid Function Tests | 1 | 2012 | 288 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2003 | 13446 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2008 | 10194 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2018 | 1779 | 0.020 |
Why?
|
Pigmentation | 1 | 2011 | 144 | 0.020 |
Why?
|
Growth Disorders | 1 | 2015 | 655 | 0.020 |
Why?
|
Hepatic Duct, Common | 1 | 2010 | 48 | 0.020 |
Why?
|
Blister | 1 | 2010 | 86 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2023 | 4937 | 0.020 |
Why?
|
Placebos | 1 | 2014 | 1667 | 0.020 |
Why?
|
Viral Load | 2 | 2010 | 3332 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2003 | 17635 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2005 | 4481 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 13642 | 0.020 |
Why?
|
Postoperative Hemorrhage | 1 | 2013 | 415 | 0.020 |
Why?
|
Vitamin D | 2 | 2014 | 3303 | 0.020 |
Why?
|
Sclerosis | 1 | 2010 | 210 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2003 | 4758 | 0.020 |
Why?
|
Thyroxine | 1 | 2013 | 666 | 0.020 |
Why?
|
Hypersensitivity, Immediate | 1 | 2012 | 347 | 0.020 |
Why?
|
Vasoconstrictor Agents | 1 | 2013 | 654 | 0.020 |
Why?
|
Hepatic Artery | 1 | 2010 | 232 | 0.020 |
Why?
|
Middle Aged | 5 | 2012 | 220921 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2013 | 592 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2005 | 15266 | 0.020 |
Why?
|
Venules | 1 | 2009 | 161 | 0.020 |
Why?
|
Anastomosis, Surgical | 1 | 2012 | 983 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2012 | 1596 | 0.020 |
Why?
|
Mutation | 1 | 2013 | 30053 | 0.020 |
Why?
|
Drainage | 1 | 2014 | 1157 | 0.020 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2011 | 506 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2013 | 12059 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 1998 | 1809 | 0.020 |
Why?
|
Drug Therapy, Combination | 2 | 2010 | 6312 | 0.020 |
Why?
|
Vulnerable Populations | 1 | 2013 | 703 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2012 | 12149 | 0.020 |
Why?
|
Adolescent Health Services | 1 | 2009 | 218 | 0.020 |
Why?
|
Portal Vein | 1 | 2010 | 431 | 0.020 |
Why?
|
Physicians | 1 | 2005 | 4591 | 0.020 |
Why?
|
Kidney | 1 | 2003 | 7048 | 0.020 |
Why?
|
Hormone Replacement Therapy | 1 | 2013 | 751 | 0.020 |
Why?
|
Immunoglobulin M | 1 | 2012 | 1526 | 0.020 |
Why?
|
Aged | 4 | 2012 | 169310 | 0.020 |
Why?
|
Vitamins | 1 | 2014 | 1635 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2012 | 1241 | 0.020 |
Why?
|
Depression | 1 | 2005 | 8126 | 0.020 |
Why?
|
Dermatitis, Atopic | 1 | 2012 | 731 | 0.010 |
Why?
|
Drug Resistance, Viral | 1 | 2010 | 862 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 2009 | 756 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2002 | 20100 | 0.010 |
Why?
|
Rhinitis | 1 | 2012 | 747 | 0.010 |
Why?
|
Hospitals, Pediatric | 1 | 2013 | 1860 | 0.010 |
Why?
|
Social Class | 1 | 2013 | 2004 | 0.010 |
Why?
|
Survivors | 1 | 2014 | 2371 | 0.010 |
Why?
|
Body Height | 1 | 2010 | 1570 | 0.010 |
Why?
|
Social Support | 1 | 2013 | 2172 | 0.010 |
Why?
|
HIV Infections | 1 | 2010 | 17354 | 0.010 |
Why?
|
Psychological Tests | 1 | 2005 | 640 | 0.010 |
Why?
|
Hepatocytes | 1 | 2010 | 1233 | 0.010 |
Why?
|
Risk Reduction Behavior | 1 | 2009 | 1112 | 0.010 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2008 | 829 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2013 | 5247 | 0.010 |
Why?
|
Antigen-Antibody Reactions | 1 | 2002 | 340 | 0.010 |
Why?
|
DNA, Viral | 1 | 2009 | 2202 | 0.010 |
Why?
|
Binding Sites, Antibody | 1 | 2002 | 337 | 0.010 |
Why?
|
Immune Sera | 1 | 2002 | 606 | 0.010 |
Why?
|
Cross-Sectional Studies | 2 | 2013 | 26129 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2010 | 4807 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13255 | 0.010 |
Why?
|
Binding, Competitive | 1 | 2002 | 1141 | 0.010 |
Why?
|
Venous Thrombosis | 1 | 2010 | 1303 | 0.010 |
Why?
|
Renal Dialysis | 1 | 2010 | 1796 | 0.010 |
Why?
|
Attitude | 1 | 2005 | 775 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2005 | 13381 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2010 | 6534 | 0.010 |
Why?
|
Up-Regulation | 1 | 2009 | 4125 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2015 | 4235 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6484 | 0.010 |
Why?
|
Cause of Death | 1 | 2010 | 3683 | 0.010 |
Why?
|
Pregnancy | 1 | 2021 | 29890 | 0.010 |
Why?
|
Algorithms | 1 | 2020 | 14033 | 0.010 |
Why?
|
Kidney Diseases | 1 | 2010 | 2091 | 0.010 |
Why?
|
Surface Properties | 1 | 2002 | 1161 | 0.010 |
Why?
|
Communication | 1 | 2013 | 3875 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2002 | 1693 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2013 | 12463 | 0.010 |
Why?
|
Age Distribution | 1 | 2004 | 2879 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2002 | 2748 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 1997 | 372 | 0.010 |
Why?
|
Thrombosis | 1 | 2010 | 2942 | 0.010 |
Why?
|
Genotype | 1 | 2010 | 12990 | 0.010 |
Why?
|
Incidence | 1 | 2013 | 21355 | 0.010 |
Why?
|
Heart Transplantation | 1 | 2008 | 3233 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2012 | 22176 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 11742 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2002 | 3733 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 2013 | 5821 | 0.010 |
Why?
|
Depressive Disorder | 1 | 2005 | 3728 | 0.010 |
Why?
|
Models, Molecular | 1 | 2002 | 5439 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2002 | 3713 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 1997 | 2850 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2012 | 58984 | 0.000 |
Why?
|